PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Net Income | -136.58M | -154.37M | -108.81M | -- | -- |
| Total Depreciation and Amortization | 2.93M | 4.05M | 4.41M | -- | -- |
| Total Amortization of Deferred Charges | 1.95M | 3.85M | 5.59M | -- | -- |
| Total Other Non-Cash Items | 108.14M | 110.59M | 56.31M | -- | -- |
| Change in Net Operating Assets | -27.67M | -20.48M | -13.47M | -- | -- |
| Cash from Operations | -51.23M | -56.35M | -55.98M | -- | -- |
| Capital Expenditure | -494.00K | -835.00K | -814.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.95M | 76.51M | 23.52M | -- | -- |
| Cash from Investing | 45.46M | 75.68M | 22.71M | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -116.73M | -124.19M | -124.19M | -- | -- |
| Issuance of Common Stock | 461.00K | 461.00K | -- | -- | -- |
| Repurchase of Common Stock | -50.38M | -55.01M | -61.84M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.00K | -9.00K | -9.00K | -- | -- |
| Other Financing Activities | 3.49M | -207.00K | -207.00K | -- | -- |
| Cash from Financing | -163.18M | -178.95M | -186.24M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -168.95M | -159.62M | -219.51M | -- | -- |